SION
Sionna Therapeutics, Inc. Common StockKey Statistics
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of therapies for neurodegenerative diseases, with a particular emphasis on addressing protein misfolding and aggregation associated with conditions such as Alzheimer's and Parkinson's diseases. Leveraging its proprietary technologies and a robust scientific foundation, Sionna is building a promising pipeline aimed at fulfilling the substantial unmet medical needs within this therapeutic area. The company's commitment to research and development, coupled with strategic collaborations, positions it as a significant player in the biopharmaceutical landscape, focused on improving the quality of life for patients suffering from these challenging neurological disorders.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-88.33M |
| Operating Margin | 0.00% |
| Return on Equity | -31.80% |
| Return on Assets | -21.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.86 |
| Price-to-Book | 5.94 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $45.00M |
| Float | $15.78M |
| % Insiders | 6.87% |
| % Institutions | 98.16% |